Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3

• Published in: Frontiers in oncology Vol. 13; p. 1097309
• Main Authors: Rapoport, Bernardo L., Steel, Helen C., Benn, Carol A., Nayler, Simon, Smit, Teresa, Heyman, Liezl, Theron, Annette J., Hlatshwayo, Nomsa, Kwofie, Luyanda L.I., Meyer, Pieter W.A., Anderson, Ronald
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.03.2023
• Subjects: breast cancer; co-inhibitory checkpoints; co-stimulatory checkpoints; cytotoxic T cells; immune dysregulation; immunotherapy; Oncology; neoadjuvant chemotherapy; co-stimulatory checkpoints; co-inhibitory checkpoints; immunotherapy; breast cancer; cytotoxic T cells; immune dysregulation
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1097309

Neoadjuvant chemotherapy (NAC) may alter the immune landscape of patients with early breast cancer (BC), potentially setting the scene for more effective implementation of checkpoint-targeted immunotherapy. This issue has been investigated in the current study in which alterations in the plasma conc...